Introduction Cancer of Unknown Primary (CUP) diagnostics is a critical area for oncologists and researchers, as 2-5% of cancer cases…
Browsing: Prostate Cancer Treatment
Prostate Cancer Treatment Resources
Prostate cancer treatment is advancing rapidly, and OncologyTube’s Prostate Cancer Treatment category is your trusted source for the latest updates. Discover expert-led videos, clinical trial insights, and research from leading oncologists. Whether you’re exploring androgen deprivation therapy, immunotherapy, or surgical options like radical prostatectomy, our curated content supports patients and professionals alike. Learn about innovations like PSMA-targeted therapies and the PROSTVAC trial for advanced prostate cancer.
Why Trust OncologyTube?
We feature renowned experts like Dr. Mansoor Raza Mizra, a leader in oncology, delivering credible and actionable insights. Our partnerships with top institutions ensure reliable, up-to-date information.
Latest Prostate Cancer Research
Stay informed with breakthroughs, such as ESMO 2025 updates on enzalutamide and darolutamide. Our videos simplify complex topics like PSA testing and MRI-guided biopsies for patients and caregivers.
Patient and Professional Resources
OncologyTube provides resources for both patients and providers. Patients can access support tools, while professionals find updates on guidelines from ASCO and EAU. Watch interviews addressing treatment challenges and solutions.
Explore More
Dive into related content like Dr. Mizra’s video on advanced prostate cancer or visit our Immunotherapy Category. For guidelines, explore the National Cancer Institute or ASCO.
Former President Joe Biden’s Stage 4 prostate cancer diagnosis, announced on May 27, 2025, raises profound questions. When did this…
Introduction: A Milestone Achievement for Dr. Peter Zang Peter Zang, MD, a second-year fellow at City of Hope, has reached…
MRI’s Role in Prostate Cancer Diagnosis – A 3-Year Study Breakthrough Date: February 20, 2025 Prostate cancer, the second most…
Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a…
Warning: Undefined array key "file" in /home2/medicusn/public_html/.website_03b234a0/wp-content/themes/smart-mag/inc/media.php on line 688
… [VIDEO & SLIDES] Alex Chehrazi –Raffle, MD, City of Hope – 2024 MOASC Annual Oncology Summit & Research Symposium…
By. Tyler Ames, PhDDate. November 01, 2023Tyler Ames, Ph.D. in oncology research, delves into the intricate mechanisms of PT-112’s impact…
Author: Dr. Oliver Sartor (on-camera comments) – Courtesy of ESMO.org At ESMO 2023, an opportunity arose to present new data…
By: Neal Shore, MD Date: October 25, 2023 In the abstract describing the EMBARK Phase 3 trial, Dr. Neal Shore…
Jalen Patel, MD – City of Hopeaugust 21, 2023Drawing from data provided by ASCO and Friends of Cancer Research, the…
Welcome to our in-depth exploration of a topic of big importance in the field of oncology: Metastatic Castration-Resistant Prostate Cancer…
Jonathan David Tward ,MD, PHD, FASTRO – University of Utah A study using the Prolaris test shows that it can…
Scott T Tagawa, MD, MS, FASCO, FACP – Weill Cornell This study explores the use of a combination therapy, involving…
Prof. Arun Azad, MBBS, PhD from the Peter MacCallum Cancer Centre, has recently conducted a Phase 3 clinical trial called…
CAR T-cell: Advances in Adoptive Therapies for Targeting Heterogeneity in mCRPC Lupita Lopez By Lupita Lopez, BS Ph.D. candidate at…
For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University…
For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…
For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…
For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…
For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…
For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an…
iFrame is not supported! MIRAGE Trial Phase 3: CT / MRI SBRT Which is Better? [2022] Which is Better: CT…
MIRAGE Trial Phase 3: CT / MRI SBRT Which is Better? [2022] Which is Better: CT or MRI SBRT in…
iFrame is not supported! Cribriform CAP Intraductal Carcinoma Prostate [2022] Cribriform Prostate Cancer Clinical Trial I’m here to talk…
Cribriform CAP Intraductal Carcinoma Prostate [2022] Cribriform Prostate Cancer Clinical Trial I’m here to talk about our recent study,…
DASL-HiCaP Phase 3 Trial [2022]: Update David Wise MD Â David Wise, MD Spoke with OncologyTube about the DASL-HiCaP (randomised)…
Lutetium-177–PSMA-617 [2022]: Update David Wise MD  So Lutetium-PSMA-617 ((lu psma 617) prostate specific membrane antigen), we’ll call it 617…
ASCO 2022 Prostate Cancer Overview: MOASC Spotlight  ARASENS Trial I presented at MOASC three datasets in prostate cancer from…
Are you aware that Black men continue to suffer worse outcomes compared to White men with prostate cancer? Through this…
Dr. Daniel Kwon, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video…
Dr. Daniel Kwon, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video…
Dr. Daniel Kwon, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video…
This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the…
This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the…
This educational activity features a panel consisting of an oncologist as well as leading experts (a urologist and a researcher)…
Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center.…
Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center.…
Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at…
Howard M. Sandler, MD, Ronald H. Bloom Family Chair, Cancer Therapeutics, Chair, Department of Radiation Oncology, Professor, Radiation Oncology at…
Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of…
Spyridon Basourakos, MD, Urology Resident 5th year at Weill Cornell Medicine, Jonathan E. Shoag, MD, Adjunct Clinical Assistant Professor of…
Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI),…
Neeraj Agarwal, MD, Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI),…
Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022…
Sanika Bodas, Ph.D., Ph.D. Student at University of Nebraska Medical Center. In this video, she speaks about the AACR 2022…
Linda Kachuri, PhD, Postdoctoral Scholar, Epidemiology & Biostatistics at UC San Francisco. In this video, she speaks about the AACR…
Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science…
Alberto Anel, Ph.D., Professor of Biochemistry, Department of Biochemistry and Molecular and Cellular Biology, Biochemistry and Molecular Biology Area, Science…
Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close…
Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close…
Professor Fred Saad, MD, FRCS, Professor, and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal…
Professor Fred Saad, MD, FRCS, Professor, and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal…
Alicia K. Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program Dana-Farber Cancer Institute. In this video, she…
Alicia K. Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program Dana-Farber Cancer Institute. In this video, she…
Anna Woloszynska, Ph.D., Associate Professor of Oncology in Roswell Park’s Department of Pharmacology and Therapeutics. In this video, she speaks…
Anna Woloszynska, Ph.D., Associate Professor of Oncology in Roswell Park’s Department of Pharmacology and Therapeutics. In this video, she speaks…
Dhyan Chandra, Ph.D., Associate Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park Cancer Center. In this video,…
Dhyan Chandra, Ph.D., Associate Professor of Oncology, Department of Pharmacology & Therapeutics at Roswell Park Cancer Center. In this video,…
Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision…
Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision…
Nima Sharifi, MD, Director, Center for GU Malignancies Research at the Cleveland Clinic speaks about Gut Microbiome-Dependent Metabolic Pathways and…
Nima Sharifi, MD, Director, Center for GU Malignancies Research at the Cleveland Clinic speaks about Gut Microbiome-Dependent Metabolic Pathways and…
Alan Dal Pra, MD from the University of Miami – Sylvester Cancer Center, Clinical Director, Director, Radiation Oncology Clinical Research…
Alan Dal Pra, MD from the University of Miami – Sylvester Cancer Center, Clinical Director, Director, Radiation Oncology Clinical Research…
Dr. Hans Van der Voet Consultant Oncologist and Principal Investigator Panthera Biopartners speaks about Panthera@theRutherford clinical trial partnership has commenced…
Dr. Hans Van der Voet Consultant Oncologist and Principal Investigator Panthera Biopartners speaks about Panthera@theRutherford clinical trial partnership has commenced…
Amar U. Kishan, MD, Associate Professor, is the Vice Chair of Clinical and Translational Research and Chief of the Genitourinary…
Amar U. Kishan, MD, Associate Professor, is the Vice Chair of Clinical and Translational Research and Chief of the Genitourinary…
Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine at Penn Medicine speaks about the Association of Inherited Mutations in…
Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine at Penn Medicine speaks about the Association of Inherited Mutations in…
Paul L. Nguyen, MD, Professor, Radiation Oncology, Harvard Medical School, Vice-Chair for Clinical Research, Genitourinary Disease Cancer Leader for Radiation…
Paul L. Nguyen, MD, Professor, Radiation Oncology, Harvard Medical School, Vice-Chair for Clinical Research, Genitourinary Disease Cancer Leader for Radiation…
Eric Klein, MD from the Glickman Urological and Kidney Institute at the Cleveland Clinic speaks about the AUA 2021 Abstract…
Eric Klein, MD from the Glickman Urological and Kidney Institute at the Cleveland Clinic speaks about the AUA 2021 Abstract…
Andrew J. Armstrong, MD, Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute speaks about the ESMO 2021…
Andrew J. Armstrong, MD, Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute speaks about the ESMO 2021…
Stella K. Kang, MD of the Departments of Radiology, NYU Langone Health speaks about Active Surveillance Strategies for Low-Grade Prostate…
Neeraj Agarwal, MD, is a Professor in the Division of Oncology, Department of Medicine, at the Huntsman Cancer Institute at…
Shilpa Gupta, MD from the Cleveland Clinic speaks about the ASCO 2021 Abstract – SWOG S1216: A phase III randomized…
Stella K. Kang, MD of the Departments of Radiology, NYU Langone Health speaks about Active Surveillance Strategies for Low-Grade Prostate…
Neeraj Agarwal, MD, is a Professor in the Division of Oncology, Department of Medicine, at the Huntsman Cancer Institute at…
Neeraj Agarwal, MD, is a Professor in the Division of Oncology, Department of Medicine, at the Huntsman Cancer Institute at…
Shilpa Gupta, MD from the Cleveland Clinic speaks about the ASCO 2021 Abstract – SWOG S1216: A phase III randomized…
Nima Sharifi, MD, director of Cleveland Clinic’s Genitourinary Malignancies Research Center speaks about Cleveland Clinic Researchers Identify New Drug Target…
Watch our interview with Dr. Howard Soule and Dr. Becky Campbell from the Prostate Cancer Foundation talking about their new…
Veerle Groen, MD from the University Medical Center Utrecht, Radiation Oncology, Utrecht, the Netherlands speaks about Focal Boost to the…
Jonathan Simons, MD, President, and CEO of the Prostate Cancer Foundation speaks about Study Training Dogs to Detect Prostate Cancer…
Tyler Seibert, MD, Ph.D. Principal Investigator and Assistant Professor at UC San Diego School of Medicine and radiation oncologist at…
Samuel R. Denmeade, MD of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins discusses TRANSFORMER: A Randomized Phase II…
Felix Y. Feng, MD, professor of radiation oncology, urology, and medicine from the University of California, San Francisco speaks about…
Jonathan D. Tward, MD, Ph.D. from the Huntsman Cancer Institute and U Health – University of Utah speaks about New…
Ashley E Ross, MD, Ph.D. From Northwestern University Feinberg School of Medicine speaks about Practical Applications of Novel Imaging and…
Kim Chi, MD, Vice President & Chief Medical Officer of BC Cancer speaks about TITAN: A final analysis with close…
Matthew Smith, MD, Professor of Medicine of Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General…
Matthew Smith, MD, Professor of Medicine of Harvard Medical School and Director of the Genitourinary Malignancies Program at Massachusetts General…
Clayton S. Lau, MD of the City of Hope speaks about Prostate Cancer: His Experience, Research, And The Current Treatment…
Arun Azad, Ph.D., MBBS, FRACP from Peter MacCallum Cancer Centre, discusses mHSPC Management, ESMO, Ongoing and Upcoming Clinical Trials in…
Professor Ray McDermott of St. Vincent University Hospital and Tallaght Hospital, Ireland explains the ESMO poster DASL-HiCaP: Darolutamide augments standard…
Dr. Neal Shore MD, FACS, CPI, of the Atlantic Urology Clinics and Director at the Carolina Urologic Research Center, discusses…
Neal Shore, MD at the Carolina Urologic Research Center discusses the ESCALATE Trial Potential Enhancement of Prostate Cancer Treatment Options:…
Steve Shak Exact Sciences Chief Medical Officer discusses Oncotype DX Genomic Prostate Score® Result Shows for the First Time the…
Matthew Galsky, MD from Mount Sinai Tisch Cancer discusses an ASCO 2020 abstract entitled Phase III IMvigor 130 Study Tumor,…
Eleni Efstathiou, MD, Ph.D. of MD Anderson discusses an ASCO 2020 abstract entitled Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with…
Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Olaparib for Metastatic Castration-Resistant Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Neal Shore, MD, FACS – LUGPA discusses Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
Nicholas J. Vogelzang, MD Comprehensive Cancer Centers of Nevada discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Huma Q. Rana, MD of Dana Farber Cancer Institute @DanaFarber discusses a randomized controlled trial of video-education or in-person genetic…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses DARolutamide observationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC)…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses darolutamide and enzalutamide effects on physical and neurocognitive function and…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the safety outcomes of darolutamide versus apalutamide and enzalutamide in…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of…
Andrew Krivoshik, MD of Astellas @AstellasUS discusses the long-term results of the phase III ADMIRAL trial presented at this year’s…
Andrew Krivoshik, MD of Astellas @AstellasUS discusses the importance of the phase III PROSPER trial in the prostate cancer community…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Mark Wildgust, VP of Janssen @JanssenUS discusses ERLEADA (apalutamide) significantly improving overall survival in patients with non-metastatic castration-resistant prostate cancer:…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer and…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. How…
Himisha Beltran, MD of Dana Farber @DanaFarber discusses circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. Read…
Earn CME: https://www.naccme.com/program/19-cpc-101-5 This webcast features a presentation by Dr. Atish D. Choudhury that examines the latest clinical safety and…
Ron Peck, MD, CMO of Arvinas @Arvinas on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic…
Ron Peck, MD, CMO of Arvinas @Arvinas answers common questions on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat…
Ron Peck, MD, CMO of Arvinas @Arvinas discusses the initial safety and PK data on an orally-active proteolysis targeting chimera (PROTAC) molecule…
Ron Peck, MD, CMO of Arvinas @Arvinas discusses an orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic…
Dr. Mark Tuthill, MD of University of Oxford explains the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy…
Dr. Mark Tuthill, MD of University of Oxford answers the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy:…
Dr. Mark Tuthill, MD of University of Oxford discusses the ADVANCE, Phase 2a data, testing VTP-800 on prostate cancer immunotherapy.…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews explains the phase II trial in effective immunotherapy with markers of immune activation…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews answers if the markers are predictive of outcomes on immunotherapy with markers of…
Dr. Sumit Subudhi, M.D., Ph.D. of @MDAndersonNews discusses effective immunotherapy with markers of immune activation in metastatic prostate cancer. While…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to…
Neal Shore, MD of Carolina Urologic Research Center @AtlanticUrology explains the randomized phase II study of sipuleucel-T with or without radium-223: how…
Neal Shore, MD of Carolina Urologic Research Center explains the randomized phase II study of sipuleucel-T with or without radium-223…
Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO…
Neal Shore, MD of Carolina Urologic Research Center explains CBF in regions relevant to cognitive function with ENZA to DARO…
Neal Shore, MD of Carolina Urologic Research Center explains cerebral blood flow (CBF) in regions relevant to cognitive function with…
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: the importance of mutation testing.
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: how this affects clinicians, patients and treatment today.
Arlene Siefker-Radtke, MD of @MDAndersonNews answers the phase 1b/2 NORSE study: does FGFR targeted therapy work better than an immune…
Arlene Siefker-Radtke, MD of @MDAndersonNews discusses the phase 1b/2 NORSE study on the treatment of metastatic urothelial carcinoma in patients…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses HSD3B1(1245C) – how this affects clinicians and treatment today. _________ In a…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic answers common questions between genetic variant and poor outcomes in men with metastatic…
Nima Sharifi, MD @nimasharifimd of @CleClinicMD @ClevelandClinic discusses a link between genetic variant and poor outcomes in men with metastatic…
Two-drug combination effective in lab studies against aggressive prostate tumors Research team identifies new approach to treating prostate cancer Metabolic…
In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with…
First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses the impact of therapy…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam…
Soumyajit Roy, MBBS @SouMyajiT_RO of University of Ottawa Division of Radiation Oncology, Department of Radiology discusses androgen-deprivation therapy with external-beam…
Androgen Deprivation Therapy (ADT) for Men with Prostate Cancer GRACE is very excited to bring to more info from our…
Study results support development of LRIG1 as novel anti-cancer therapeutic Study is first to report that LRIG1 suppresses prostate cancer…
Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS on how the ProVent trial might change the AS treatment landscape.…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS provides insight on current treatment options for men in the phase…
Neal Shore, MD of Carolina Urologic Research Center @UrologyUS discusses the phase 3 provent clinical trial. ____________ Dendreon Pharmaceuticals, a…
Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic,…
– Target Enrollment of 450 Achieved Early Due to High Demand – – Topline Results Expected in 2023 – Dendreon…
Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic,…
A research study published in Neoplasia, led by lead researcher Nallasivam Palanisamy, Ph.D., associate researcher at the Vattikuti Urology Institute…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews highlights select biomarkers in patients with prostate cancer and what is next on the…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews explains a unique biomarker can be detected in the urine samples of prostate cancer…
Nallasivam Palanisamy, Ph.D. @NallasivamPala4 of @HenryFordNews explains a biomarker in urine may offer noninvasive detection of prostate cancer. __________ A…
Sarah Osman of @Queens_Belfast explains the standardized technique is using CT scans to assess and predict prostate cancers in patients.…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate…
Researchers from Queen’s University Belfast have discovered a new way to predict the aggressiveness and future behaviour of prostate cancers.…
An international panel of experts will identify the best approaches to implement genetic testing for men with prostate cancer  …
Data published today in the New England Journal of Medicine showed that patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with…
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019…
Shauna Campbell, MD of Cleveland Clinic explains the impact of post-prostatectomy prostate specific antigen (PSA) kinetics on outcomes of salvage…
Sarmad Sadeghi, MD of USC Norris Comprehensive Cancer Center explains awaiting approval from the FDA in bladder and prostate cancer.
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the results of…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai shares details on upcoming…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai elaborates on how biomarker…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai explains the differences between…
William Oh, MD, Chief of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai discusses the outcomes of…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares on how to decide between combinations of immuno-oncology…
Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center shares the TITAN Study outcomes, investigating apalutamide in metastatic…
Nancy A Dawson MD, Professor of Medicine at Lombardi Cancer Center discusses her view on the ENZAMET Study while comparing…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency elaborates on the importance of biomarker selection trials.…
Kim Chi MD, Medical Oncologist, Senior Scientist at the BC Cancer Agency explains what came out of the metastatic castration-sensitive…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Some That Image Well Do Not Respond: BRCA2 Is…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses If They Are Imaging Negative, How Are They Responding:…
Scott Tagawa MD @drscottagawa Of Weill Cornell Medicine and NewYork-Presbyterian Discusses Targeting PSMA: Patients That Have At Least One Bright…
Mark Fleming MD Of US Oncology Research Discusses Treatment Sequencing For Castrate Resistant M0 Disease: Looking At 3 Drugs Enzalutamide,…
Mark Fleming MD Of US Oncology Research Discusses TITAN Trial: Many Options Including Chemo, Abiraterone, Enzalutamide, & Apalutamide All Showing…
Daniel George MD @daniel_j_george Of Duke University Cancer Institute Discusses Disparity Associated With Our Patient Population: African Americans Make Up…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses Molecular Tumor Boards In Clinical Practice: Increasingly Needed, GENTleMEN Study Offers…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses How To Help Men With BRCA1 & BRCA2 Mutations: Now Have…
Heather Cheng MD Of Seattle Cancer Care Alliance Discusses GENTleMEN Study: www.Gentlemen.org, Get A Saliva Kit Mailed To You &…
Kim Nguyen Chi MD Of The University Of British Colombia Discusses TITAN Study & Docetaxel: There Is Some Support To…
Kim Nguyen Chi MD Of The University Of British Colombia Discusses TITAN Study: Phase III Double-Blind, Randomized Study Of Apalutamide…
Dr. Celestia Higano, MD from the University of Washington discusses the PEACE III Trial Decreased Fracture Rate by Mandating Bone-protecting…
Dr. Celestia Higano, MD of the University of Washington discusses the Alliance A031201 a phase III trial of enzalutamide (ENZ)…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses Strength Of Talazoparib: Traps PARP On The DNA & Inhibits It…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses TALAPRO-2 Trial Patient Screening: No Need To Be Screened For Specific…
Dr. Celestia Higano, MD of the University of Washington discusses the Titan Trial Apalutamide vs Placebo During Androgen-Deprivation Therapy for…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses TALAPRO-2 Trial: Phase 3 Study Of Talazoparib (TALA) With Enzalutamide (ENZA)…
Neeraj Agarwal MD @neerajaiims Of Huntsman Cancer Institute Discusses Talazoparib + Enzalutamide Combo: Combination Is Safe & Works By Attacking…
Dr. Celestia Higano, MD of the University of Washington discusses the 10 year follow up of the Getug 16 Trial…
Dr. Ash Tewari discusses the concept of race vs. genetics in Health Disparity research and treatment
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Results…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses When…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combining…
Evan Yu, MD, Professor, Department of Medicine, Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Institute, Discusses Combination…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Sumit K. Subudhi, MD, PhD, Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses Moderate Hypofractionation & Ultra-Hypofractionation In…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses The Evolving Landscape Of Prostate…
Bridget F. Koontz, MD, Associate Professor of Radiation Oncology, Duke University School of Medicine, Discusses New Guidelines On Hypofractionated EBRT…
Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses Recent Data Utilizing LuPSMA In…
Tomasz Beer, MD, Professor of Medicine, Division of Hematology/Medical Oncology, Oregon Health Sciences University, Discusses The ARAMIS Study In nmCRPC…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses The Evolving Treatment Landscape For Patients…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses How PSA Is Valuable As A…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Data On Racial Differences In Response…
William Oh, MD, Deputy Director, The Tisch Cancer Institute, Mt. Sinai Health System, Discusses Recent Data Examining LuPSMA In Men…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The Implications Of The…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The LATITUDE Study In…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses Aramis Study In Prostate…
Mark T. Fleming, MD, Medical Oncology, Medical Director, Genitourinary Program, US Oncology, Virginia Oncology Associates, Discusses The ARCHES Trial In…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses The Evolution Of ADT In Prostate Cancer.…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Impression Of KEYNOTE 365 In mCRPC. At…
Nicholas Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, Discusses Combining Checkpoint Inhibitors In mCRPC. At The…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Phase 2 STREAM Study…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Opinion On Androgen Receptor…
Andrew Armstrong, MD Professor of Medicine, Duke Cancer Institute, Center for Prostate and Urologic Cancers, Discusses Overview Of The ARCHES…
Dr. Ashutosh Tewari discusses the nature of genetic difference and aggressiveness among African-Ameican men
Dr. Nihal Mohamed discusses research on active surveillance among high risk populations, particularly African-American
Dr. Susan Slovin discusses the newly discovered Mo stage of prostate cancer
Dr. William Oh discusses the role of PARP inhibitors in treating prostate cancer